Postoperative subconjunctival corticosteroid injection to prevent pterygium recurrence

Página do item simplificado
dc.contributor.authorParis, Fabiana dos Santos [UNIFESP]
dc.contributor.authorFarias, Charles Costa de [UNIFESP]
dc.contributor.authorMelo, Gustavo Barreto de [UNIFESP]
dc.contributor.authorSantos, Myrna Serapião dos [UNIFESP]
dc.contributor.authorBatista, Jefferson Luiz Alves [UNIFESP]
dc.contributor.authorGomes, José Álvaro Pereira [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2018-06-15T17:05:09Z
dc.date.available2018-06-15T17:05:09Z
dc.date.issued2008-05-01
dc.description.abstractPurpose: To report the outcome of postoperative subconjunctival injection of triamcinolone in eyes that underwent pterygium surgery and were at risk for recurrence.Methods: Twelve eyes of 11 patients with primary (7 eyes) or recurrent (5 eyes) pterygia underwent excision and conjunctival autografting (4 eyes, 33.3%), an-miotic membrane grafting (6 eyes, 50%), or both (2 eyes, 16.6%). All of these eyes had signs that were considered to be risk factors for recurrence (conjunctival inflammation, hemorrhage, granuloma, and fibrovascular proliferation); accordingly, they also underwent subconjunctival injection of triamcinolone.Results: Among the 11 patients, there were 8 (72.7%) men and 3 (27.3%) women; the mean age was 41 years (range, 20 - 56 years). In 5 (41.7%) eyes, the pterygium was graded as T2 (intermediate) and in 7 (58.3%) eyes was graded as T3 (fleshy). The time between surgery and the first injection ranged from 2 to 5 weeks (mean, 3.4 weeks), and 1 - 3 injections were necessary (mean, 1.7) to achieve the desired effect. After injection, 1 (8.3%) eye developed inflammation, and 2 (16.7%) eyes from another patient developed intraocular hypertension that was controlled with a topical P-blocker. The follow-up after the last injection ranged from 8 to 36 months (mean, 14.5 months); only 1 recurrence (grade 3) occurred during this period.Conclusions: The postoperative use of subconjunctival triamcinclone seems to benefit patients at increased risk of pterygium recurrence. It is relatively safe and is accompanied by few complications, but controlled and prospective studies are necessary to confirm its efficacy.en
dc.description.affiliationUniv Fed Sao Paulo, Dept Ophthalmol, External Dis & Cornea Serv, BR-04023062 Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Dept Ophthalmol, External Dis & Cornea Serv, BR-04023062 Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent406-410
dc.identifierhttps://dx.doi.org/10.1097/ICO.0b013e318162af90
dc.identifier.citationCornea. Philadelphia: Lippincott Williams & Wilkins, v. 27, n. 4, p. 406-410, 2008.
dc.identifier.doi10.1097/ICO.0b013e318162af90
dc.identifier.issn0277-3740
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/43422
dc.identifier.wosWOS:000255470600004
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofCornea
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectpterygiumen
dc.subjectcorticosteroidsen
dc.subjectsubconjunctivaen
dc.subjectrecurrenceen
dc.titlePostoperative subconjunctival corticosteroid injection to prevent pterygium recurrenceen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos